ENTPD1 and non-small cell lung carcinoma: Several studies have shown CXCL13+ T cells are tumour reactive (59–61) and co-expression of CD39 and CXCL13 allows effective enrichment of tumour reactive CD4+ T cells in NSCLC (59).